- Home
- GHI vs CUE Comparison
GHI vs CUE Comparison
Compare GHI & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GHI
Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Current Price
Company Overview
Basic Information| Metric | GHI | CUE |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.3M | 124.5M |
| IPO Year | 1998 | 2017 |
Fundamental Metrics
Financial Performance| Metric | GHI | CUE |
|---|---|---|
| Price | $5.81 | $27.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $10.50 | ★ $120.00 |
| AVG Volume (30 Days) | 60.8K | ★ 160.0K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | ★ 22.93% | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $85,389,766.00 | $27,466,000.00 |
| Revenue This Year | $273.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $578.00 | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $4.71 | $0.17 |
| 52 Week High | $11.12 | $45.50 |
Technical Indicators
Market Signals| Indicator | GHI | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 59.42 | 44.09 |
| Support Level | $5.05 | $24.49 |
| Resistance Level | $6.16 | $33.73 |
| Average True Range (ATR) | 0.22 | 3.15 |
| MACD | 0.07 | -0.78 |
| Stochastic Oscillator | 69.70 | 16.97 |
Price Performance
Historical ComparisonAbout GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.